Metabolic syndrome and benign prostatic hyperplasia: An update

Ngai, Ho‐Yin; Yuen, Kar-Kei Steffi; Ng, Chi-Man; Cheng, Cheung‐Hing; Chu, Sau-Kwan Peggy

doi:10.1016/j.ajur.2017.05.001

Cited by 43 publications

(46 citation statements)

References 107 publications

(126 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A re‐consideration of some of the aetiological factors may help shed light on the need to re‐examine some old and new biomarkers. Metabolic syndrome (MetS) is a common feature of the two conditions (Gacci et al, ; Ngai, Yuen, Ng, Cheng, & Chu, ). The role of lipids in the pathogenesis of BPH and PCa is also an established fact.…”

Section: Introductionmentioning

confidence: 99%

“…Metabolic syndrome itself is made up of various factors such as visceral adiposity, dyslipidaemia, endothelial dysfunction and insulin resistance (Kaur, ). These metabolic abnormalities may then promote the development of BPH and LUTS (Ngai et al, ). Furthermore, accumulation and faster synthesis of cholesterol in prostate cells compared to the liver have been demonstrated (Krycer & Brown, ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oxidised low‐density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia

et al. 2019

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) share common conditions such as lower urinary tract symptoms (LUTS) and dyslipidaemia. Whether an extensive lipid profile analysis could discriminate between BPH and PCa was the objective. Thirty‐six (36) BPH and twenty (20) PCa outpatients of a urology clinic plus forty (40) controls without LUTS, but normal PSA, were recruited. Body mass index (BMI), lipid profile (total cholesterol [CHOL], triglycerides [TG], high‐density lipoprotein [HDL], very‐low‐density lipoprotein [VLDL], low‐density lipoprotein [LDL] and Castelli's risk index I [CR I] [TC/HDL]), oxidised LDL, apolipoprotein E, ceramide and PSA were determined. Mean ages for BPH, PCa and control were 69 ± 13, 67 ± 10 and 53 ± 7 years respectively. Most parameters apart from BMI and HDL were significantly different compared to the control group. oxLDL for BPH versus control, PCa versus control and BPH versus PCa was significant (p < 0.001, p = 0.02 and p < 0.001 respectively). Ceramide showed significant group differences. Between BPH and PCa, total cholesterol, LDL and Apo E were significantly different (p = 0.00, p = 0.01 and p = 0.03 respectively). Apo E could potentially be a discriminating biomarker. Receiver operating characteristic curves for TPSA, Apo E and oxLDL demonstrated sensitivity of 69.44 and specificity of 88.24 for oxLDL, hence more discriminatory.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Oxidised low‐density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia

et al. 2019

View full text Add to dashboard Cite

show abstract

“…For macronutrients, increased total energy intake, energy-adjusted total protein intake, red meat, fat, milk and dairy products, cereals, bread, poultry and starch potentially increase the risks of symptomatic BPH, while vegetables (particularly carotenoids), fruits, polyunsaturated fatty acids, linoleic acid, lutein, Vitamin C, Vitamin A and Vitamin D potentially decrease the risks of symptomatic BPH and LUTS. [25][26][27] Based on the studies reviewed, a holistic framework has been suggested in ►Fig. 1.…”

Section: Discussionmentioning

confidence: 99%

A Multidisciplinary Management Framework for the Treatment of Benign Prostatic Hyperplasia with Focus on Homoeopathy: A Review

Karso

2020

Homœopathic Links

View full text Add to dashboard Cite

Background Benign prostatic hyperplasia (BPH) is a globally prevailing urological condition among ageing men. In India, a few epidemiological studies conducted on BPH patients suggest it as the most common pathological condition with an incidence of around 93.3%. Although non-malignant, the condition adversely impacts the quality of life (QoL) in a way similar to that of other non-communicable diseases like diabetes, hypertension and cardiovascular diseases. Objective This article aims to review the comprehensive management of BPH with focus on homoeopathic treatment. Methods PubMed, EMBASE, Google Scholar, AYUSH PORTAL and leading homoeopathic journals were searched for articles on BPH and its homoeopathic management. Results The review offers a holistic framework for management of BPH that is inclusive of modifiable lifestyle factors alongside homoeopathic treatments. It further underscores that the condition may be cost-effectively managed through homoeopathy to bring about better QoL among people with BPH. Conclusion Lifestyle optimisation and management of metabolic risk factors may reduce the progression of BPH. Homoeopathic medicines are not only useful in effective management of BPH but also cost-effective, safe and non-surgical. However, randomised controlled trials and double-blind studies can be further taken up in future for more precise authentication.

show abstract

“…Nevertheless, the current standard pharmacotherapy of PA is often not effective enough for a number of patients, especially those with systemic hormonal and metabolic disorders (obesity, insulin resistance, testosterone deficiency, vitamin D deficiency), which tends to increase in frequency in the male population and significantly reliably correlate with one another, as well as with the frequency and severity of PA (Park et al 2008;Gorbachinsky et al 2010;Vignozzi et al 2012;Espinosa 2013;Tyuzikov and Kalinichenko 2016;Udensi and Tchounwou 2016;Wang et al 2016;Zou et al 2016;Ngai et al 2017).…”

Section: Introductionmentioning

confidence: 99%

Optimization of pharmacotherapy of patients with prostate adenoma with hormonal and metabolic disordes: correction of vitamin D deficiency with “Aquadetrim”

Братчиков¹,

Tyuzikov²,

Artishchev³

2019

RRP

View full text Add to dashboard Cite

Citation: Bratchikov OI, Tyuzikov IA, Artishchev SO (2019) Optimization of diagnostics and management of patients with prostate adenoma with hormonal and metabolic disorders on the basis of integrative approach. Research Results in Pharmacology 5(4): 57-67. https://doi. AbstractIntroduction: Modern studies demonstrate an epidemiological and pathogenetic role of systemic hormonal and metabolic disorders in men with prostate adenoma (PA), so it is obvious that a pharmacotherapeutic correction of these disorders can increase the efficacy of the traditional therapy of the disease. Aim of study:To investigate the frequency, relationships among themselves and with PA local parameters of key systemic hormonal and metabolic disorders (obesity, insulin resistance, testosterone deficiency, vitamin D deficiency) and to develop practical algorithms for optimizing diagnosis and management based on an integrative approach. Material and Methods:The results of a comprehensive examination of 160 patients with PA (main group; average age 62.3 ± 4.2 years) and 30 healthy men without PA of the same age (control group), including: collection of anamnesis and complaints; questionnaires; physical, hormonal and sonographic studies, -are presented. Pharmacotherapeutic correction methods were tested in some patients of the main group. The data was processed using descriptive and comparative statistics. Results and Discussion:In the patients with PA, a significantly higher frequency of concomitant systemic hormonal and metabolic disorders formed at a younger age was established, compared to the men without PA, and significantly worse local characteristics of PA compared to the patients with PA without such (p < 0.05). Reliable connections of some studied systemic hormonal and metabolic disorders with one another and with local parameters of PA (p < 0.05) were revealed. A more severe vitamin D deficiency in the patients with PA compared to the control group was revealed, and the safety and a significant positive effect of its drug compensation on the parameters of hormonal and metabolic status and PA in D-deficient men with PA were shown (p < 0.05). Conclusion:The results of the study confirm an important role of the studied systemic hormonal and metabolic disorders in the pathogenesis of PA and the need for their diagnosis and pharmacotherapeutic correction in all patients with PA on the basis of an integrative approach, according to the proposed algorithms.

show abstract

Metabolic syndrome and benign prostatic hyperplasia: An update

Cited by 43 publications

References 107 publications

Oxidised low‐density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia

Oxidised low‐density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia

A Multidisciplinary Management Framework for the Treatment of Benign Prostatic Hyperplasia with Focus on Homoeopathy: A Review

Optimization of pharmacotherapy of patients with prostate adenoma with hormonal and metabolic disordes: correction of vitamin D deficiency with “Aquadetrim”

Contact Info

Product

Resources

About